|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Medical Research Council |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00040690 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.
| Condition | Intervention | Phase |
|---|---|---|
|
Leukemia Lymphoma |
Biological: filgrastim Drug: cyclophosphamide Drug: cytarabine Drug: doxorubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: leucovorin calcium Drug: methotrexate Drug: vincristine sulfate Radiation: radiation therapy |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label |
| Official Title: | A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma |
| Estimated Enrollment: | 120 |
| Study Start Date: | November 2008 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of diffuse B-cell lymphoma in a nodal or an extranodal site
Diagnosis of bone marrow replacement/leukemia comprising mature B-cell lymphoma
Patients in the low-risk group must meet at least 3 of the following criteria:
Patients in the high-risk group must meet at least 2 of the following criteria:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Contacts and Locations| United Kingdom, England | |
| Medical Research Council Clinical Trials Unit | |
| London, England, United Kingdom, NW1 2DA | |
| Study Chair: | Simon Clawson | Medical Research Council |
More Information
| Study ID Numbers: | CDR0000069374, MRC-LY10, EU-20117 |
| Study First Received: | July 8, 2002 |
| Last Updated: | February 6, 2009 |
| ClinicalTrials.gov Identifier: | NCT00040690 History of Changes |
| Health Authority: | United States: Federal Government |
|
untreated adult acute lymphoblastic leukemia L3 adult acute lymphoblastic leukemia stage I adult Burkitt lymphoma stage III adult Burkitt lymphoma |
stage IV adult Burkitt lymphoma contiguous stage II adult Burkitt lymphoma noncontiguous stage II adult Burkitt lymphoma |
|
Anti-Infective Agents Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Neoplasms, Experimental Therapeutic Uses Abortifacient Agents Methotrexate Dermatologic Agents Etoposide Nucleic Acid Synthesis Inhibitors Immunoproliferative Disorders Immune System Diseases Vincristine Abortifacient Agents, Nonsteroidal |
Doxorubicin Herpesviridae Infections Virus Diseases Neoplasms DNA Virus Infections Lymphoma, Non-Hodgkin Antineoplastic Agents, Phytogenic Antimetabolites Immunologic Factors Antineoplastic Agents Tumor Virus Infections Leucovorin Cyclophosphamide Reproductive Control Agents Antibiotics, Antineoplastic |